Abstract | OBJECTIVE: METHODS: RESULTS: After PCI, the Thrombolysis In Myocardial Infarction myocardial perfusion grade ( TMPG) III in cilostazol group was higher than that in control group (89.19% versus 72.15%, P<0.05). At 30 days, the incidence of major adverse cardiac events was significantly lower in cilostazol group compared with that in control group (6.76% versus 17.72%, P<0.05). However, the rates of cardiac death, nonfatal reinfarction, target vessel revascularization, new congestive heart failure, and subacute stent thrombosis did not significantly differ between the two groups. In addition, the rates of minor or major bleeding or thrombocytopenia did not significantly differ between the two groups. CONCLUSION:
|
Authors | Mei Wang, Guoru Zhang, Yaling Wang, Kun Zhou, Tao Liu, Yang Zhang, Anjun Guo, Yu An, Xiaodan Zhang, Yongjun Li |
Journal | Therapeutics and clinical risk management
(Ther Clin Risk Manag)
Vol. 11
Pg. 1469-73
( 2015)
ISSN: 1176-6336 [Print] New Zealand |
PMID | 26451112
(Publication Type: Journal Article)
|